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Abstract Cerebral malaria (CM) can be classified as retinopathy-positive or retinopathy-
negative, based on the presence or absence of characteristic retinal features. While malaria
parasites are considered central to the pathogenesis of retinopathy-positive CM, their contribution
to retinopathy-negative CM is largely unknown. One theory is that malaria parasites are innocent
bystanders in retinopathy-negative CM and the etiology of the coma is entirely non-malarial.
Because hospitals in malaria-endemic areas often lack diagnostic facilities to identify non-malarial
causes of coma, it has not been possible to evaluate the contribution of malaria infection to
retinopathy-negative CM. To overcome this barrier, we studied a natural experiment involving
genetically inherited traits, and find evidence that malaria parasitemia does contribute to the
pathogenesis of retinopathy-negative CM. A lower bound for the fraction of retinopathy-negative
CM that would be prevented if malaria parasitemia were to be eliminated is estimated to be 0.93
(95% confidence interval: 0.68, 1).
DOI: 10.7554/eLife.23699.001
Introduction
Cerebral malaria (CM) is responsible for a substantial proportion of the approximately 500,000
annual malaria deaths and 2,000,000 severe malaria cases (WHO, 2014, WHO, 2015). CM is defined
by the World Health Organization (WHO) as unarousable coma with circulating malaria (Plasmodium)
parasitemia and no known non-malaria causal explanation (WHO, 2000). Based on the presence or
absence of malaria-specific retinal changes, CM can be classified as retinopathy-positive (Ret+) or
retinopathy-negative (Ret-) (Lewallen et al., 1999; Beare et al., 2006). Ret- CM is a common and
devastating condition – 40% of CM cases in our cohort were Ret- and of these, 12% died and 10%
developed neurological problems (Table 1). Autopsy data show that children dying of Ret+ CM
have a high degree of sequestration of parasitized red blood cells in cerebral vasculature
(Taylor et al., 2004), considered the pathological hallmark of CM. The pathogenesis of Ret- CM has
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been a puzzle, in particular the role of malaria parasitemia (Postels and Birbeck, 2011). In the only
autopsy study among children dying with CM, that we are aware of ( Taylor et al. (2004) with fol-
low-up results in Milner et al. (2015) and Barrera et al. (2015)), among children for whom retinopa-
thy was assessed, 41 of 42 children dying with Ret+ CM had substantial cerebral sequestration of
parasitized red blood cells in the cerebral microvasculature (defined as 23% of cerebral capillaries
had sequestration) and mostly lacked other identified potential causes of death besides the malaria
parasitemia, whereas all 15 children dying with Ret- CM lacked substantial cerebral sequestration
(<23% of cerebral capillaries had sequestration) and mostly had non-malarial etiologies of death (see
Appendix 1 for causes of death); these numbers update those in Taylor et al. (2004) to include
patients enrolled after 2004. Incidental malaria parasitemia is common in people living in areas of
high malaria transmission. Therefore, it is possible that at least some children with Ret- CM have a
non-malarial etiology of coma and an incidental (asymptomatic) malaria parasitemia. The pathogene-
sis of Ret-CM is therefore unclear, and the role of malaria parasitemia in the etiology of the acute ill-
ness is unknown (Postels and Birbeck, 2011). Our aim of the research presented here was to assess
the contribution of acute malaria infection in the pathophysiology of Ret- CM.
Figure 1 depicts three possible pathways to clinically-defined (WHO-defined) CM (Postels and
Birbeck, 2011). One pathway is to Ret+ CM for which there is evidence that malaria parasites play a
primary role. As noted above, at autopsy, Ret+ CM is associated with the sequestration of parasit-
ized red cells in the cerebral microvasculature (Taylor et al., 2004). Compared to children with Ret-
CM, those who are Ret+ have increased concentrations of P. falciparum HRP2, a parasite-produced
protein reflecting total body parasite burden (Seydel et al., 2012). Ocular funduscopic findings in
Ret+ CM mirror the microvascular pathology observed on fluorescein angiography
eLife digest Malaria is a life-threatening disease caused by a parasite that is transferred
between people by infected mosquitoes. Most infected individuals suffer flu-like symptoms, but in
rare cases malaria can affect the brain, resulting in brain damage, coma or death.
The World Health Organization defines a person as suffering from cerebral malaria if the person
is in a coma, has malaria parasites in his or her blood, and has no known alternative cause of the
coma. Patients suffering from cerebral malaria are categorized based on whether they have damage
to the back of the eyes known as retinopathy. It had previously been found that children who died
of “retinopathy-positive” cerebral malaria (i.e. those who had retinopathy) had malaria parasites
stuck in small vessels in their brains, which likely caused the coma. By contrast, children who died of
“retinopathy-negative” cerebral malaria lacked this parasitic condition, and often also had other
infections that can cause a coma, such as meningitis or sepsis.
Because hospitals in many of the areas most affected by malaria often lack the ability to identify
what – other than malaria – caused a coma, it was not clear whether malaria parasites influence how
retinopathy-negative cerebral malaria develops.
People with certain genetic variants – such as those that underlie sickle cell disease – are
protected against the symptoms of malaria infections, and so these variants should also protect
against cerebral malaria cases caused by the parasites. Small et al. therefore looked through data
that had been collected over several years from people who had been admitted to a hospital in
Malawi for cerebral malaria. This revealed that the genetically inherited sickle cell trait is highly
protective against retinopathy-negative (as well as retinopathy-positive) cerebral malaria. Therefore,
malaria parasites do play a role in a substantial proportion of cases of retinopathy-negative cerebral
malaria.
Although Small et al. provide evidence that malaria parasites play a role in retinopathy-negative
cerebral malaria, they may not be the only cause of the coma. In the future, the absence of
retinopathy could be used as a sign to look for additional factors that contribute to the coma.
Currently, all cerebral malaria patients are treated in the same way. Understanding how malaria
parasites interact with other illnesses to produce a coma could lead to the development of targeted
treatment plans for retinopathy-negative patients.
DOI: 10.7554/eLife.23699.002
Small et al. eLife 2017;6:e23699. DOI: 10.7554/eLife.23699 2 of 18
Short report Epidemiology and Global Health
(MacCormick et al., 2015) and are correlated with the severity of sequestration in both the retina
and the brain at autopsy (Barrera et al., 2015). Two pathways to Ret- CM, pathway (a) and pathway
(b) are depicted in Figure 1. As noted above, in patients dying with Ret- CM, the cerebral microvas-
culature does not have substantial sequestered parasitized erythrocytes (<23% of cerebral capillaries
have sequestration), plasma concentrations of HRP2 are decreased, and a variety of non-malarial
causes of death have been identified (Taylor et al., 2004). For Ret- CM, one potential pathway is
Table 1. Characteristics of study participants at admission, Means ± SD for continuous variables. The proportions of missing data are
shown in Appendix 1. There are 3704 community controls, but their characteristics are not shown because only their genotypes and
not their clinical characteristics were collected. Bold denotes p-value less than 0.05.
Retinopathy
Positive CM
Retinopathy
Negative CM
Non-Malaria
Hospital Controls
p-value,
Ret + vs. Ret -
p-value, Ret + vs.
Controls
p-value,
Ret – vs. Controls
Number of participants 438 288 204
Female 50% 52% 43% 0.54 0.11 0.05
Age (months) 40 ± 26 44 ± 30 46 ± 30 0.10 0.05 0.53
Mid-upper arm circumference (cm) 14.9 ± 1.6 15.0 ± 1.7 14.8 ± 1.8 0.72 0.53 0.39
Weight (kg) 12 ± 4 13 ± 5 13 ± 6 0.37 0.29 0.74
Height (cm) 90 ± 16 91 ± 17 91 ± 20 0.30 0.40 1.00
Temperature (˚C) 38.6 ± 1.2 38.4 ± 1.4 37.7 ± 1.5 0.03 <0.001 <0.001
Febrile (Temperature
37.5˚C)
81% 77% 56% 0.23 <0.001 <0.001
Pulse rate – beats/minute 152 ± 26 148 ± 24 139 ± 28 0.06 <0.001 <0.001
Respiratory rate – breaths/minute 47 ± 15 45 ± 13 45 ± 15 0.12 0.17 0.93
Liver size – cm below costal margin 2.0 ± 1.9 1.5 ± 1.9 1.1 ± 1.7 <0.001 <0.001 0.04
Spleen size – cm below costal margin 1.7 ± 2.1 1.6 ± 2.1 0.9 ± 1.6 0.56 <0.001 <0.001
Deep breathing 33% 25% 30% 0.03 0.59 0.18
Blantyre Coma Score:
0
1
2
3
4
5
14%
35%
49%
1%
0%
0%
19%
38%
43%
0%
0%
0%
28%
40%
23%
3%
0%
5%
0.01 0.08 0.90
CSF opening pressure – mm of water 176 ± 75 152 ± 82 176 ± 99 0.001 0.96 0.07
Hematocrit – % 19.8 ± 6.9 28.2 ± 7.5 28.1 ± 9.6 <0.001 <0.001 0.86
Platelets 81,220±
67,219
161,600±
124,747
248,400±
162,287
<0.001 <0.001 0.86
Malaria parasitemia – parasites/mm3 230,500±
321,924
180,500±
280,676
3,619±
28,917
0.03 <0.001 <0.001
White blood cells 13,040±
9163
13,020±
8923
13,930±
9544
0.97 0.29 0.31
Lactate – mmol/liter 8.6 ± 5.0 7.3 ± 4.4 5.5 ± 3.9 0.05 <0.001 0.007
Blood glucose – mmol/liter 6.1 ± 3.9 6.8 ± 4.4 7.6 ± 5.3 0.03 <0.001 0.05
CSF white cell count – %  5 16% 20% 24% 0.31 0.06 0.37
Blood culture positive for pathogen 4% 2% 14% 0.51 <0.001 <0.001
HIV positive 18% 17% 15% 0.91 0.59 0.66
Outcomes
Discharge outcome:
Full recovery
Neurological Sequalae
Died
69%
10%
21%
78%
10%
12%
57%
15%
28%
0.003 0.01 <0.001
DOI: 10.7554/eLife.23699.003
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asymptomatic parasitemia and another illness that is sufficient, in and of itself, to produce coma
(pathway (a) in Figure 1). Another potential pathway is parasitemia leading to uncomplicated malaria
illness (e.g., fever) combined with a second insult (innate or acquired), resulting in coma (pathway (b)
in Figure 1); the two hits (symptomatic malaria+ innate or acquired second factor) result in the clini-
cal syndrome of Ret- CM. A key unanswered question about the pathogenesis of Ret- CM is, are
malaria parasites incidental to coma (only pathway (a) exists) or do they play a role in the pathogene-
sis of Ret- CM (pathway (b) exists) (Bearden, 2012; Postels and Birbeck, 2011)?
Whether malaria parasites play a role in the pathogenesis of Ret- CM could in principle be tested
by a randomized experiment. For example, Smith (2007) considered a hypothetical blood-stage
malaria vaccine that reduces parasite density by 50%; the vaccine would reduce malaria illness but
not the incidence of parasitemia. If such a vaccine existed, then a way to test whether malaria para-
sites are pathogenetic in Ret- CM would be to randomize a large number of children to either (i) the
blood-stage vaccine or (ii) placebo. If malaria parasites are never pathogenetic in Ret- CM, then we
would expect no difference in Ret- CM because the blood stage vaccine would fail to prevent the
cause of the development of the Ret- CM whereas if malaria parasites are sometimes pathogenetic
in Ret- CM in a way that requires the development of uncomplicated malaria illness, then the blood
stage vaccine would prevent the development of Ret- CM in some cases. Such an experiment is not
Ret + CM
Ret - CMOTHER ILLNESS
UNCOMPLICATED
MALARIA
ILLNESS
ASYMPTOMATIC 
PARASITEMIA
Bottleneck 1:
Sickle cell trait
Bottleneck 2:
Blood group O, 
Sickle cell trait
WHO 
defined 
CM
(a)
(b)
(a) Pf infection does NOT contribute to the fever
(b) Pf infection DOES contribute to the fever
WHO 
defined 
CM
 
Figure 1. Potential pathways to clinically-defined cerebral malaria and genetic bottle necks. There are three
potential pathogenetic routes to WHO-defined cerebral malaria (CM). The first, shown in red, is the classical
pathway: a malaria infection evolves into retinopathy-positive (Ret+) CM. The second and third possibilities
produce retinopathy-negative (Ret-) CM. In (a) the coma is entirely the result of another etiology and the malaria
parasitemia is incidental. In (b), the coma is a product of the interaction between the malaria parasitemia and an
additional cause (or causes) of coma. Sickle cell trait is underrepresented in patients with Ret+ and Ret- cerebral
malaria (CM) because of the bottleneck at the transition between ’malaria infection’ (asymptomatic malaria) and
’malaria disease’ (uncomplicated malaria). Blood group O is underrepresented in patients with Ret+ CM, but not
in those with Ret- CM. Taken together, the results for sickle cell trait and blood group O suggest that some Ret-
CM cases occur through pathway (b) (because sickle cell trait is underrepresented in Ret- CM) and that malaria
parasites contribute to the pathogenesis of these cases, and that sickle cell trait reduces the pathogenetic
potential of malaria infection for Ret- CM but do not provide evidence that blood group O reduces the
pathogenetic potential of malaria infection for Ret- CM.
DOI: 10.7554/eLife.23699.004
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currently feasible because no blood-stage vaccine has reached a Phase III trial (Miura, 2016) and
even if an effective blood-stage vaccine was developed, the experiment would require a huge sam-
ple size to have power to detect a change in Ret- CM rates.
Though a randomized experiment with a blood-stage malaria vaccine that would have power to
detect a difference in Ret- CM rates is not currently feasible, nature provides traits that protect
against malaria illness in a random way through genetic inheritance. The general approach of using
genetic variation to construct natural experiments is called Mendelian randomization (Smith and
Ebrahim, 2003). The sickle cell trait (HbAS) – inheritance of one abnormal allele of the betaglobin
gene – protects against symptomatic malaria (Modiano et al., 2001; Taylor et al., 2012;
Williams et al., 2005; Willcox et al., 1983). Thus, a person who inherits one abnormal allele of the
betaglobin gene has an antimalarial biochemical protection provided by nature. A second inherited
trait which affects susceptibility to malaria illness is blood group O (BGO), which protects against
CM compared to groups A, B or AB (Cserti and Dzik, 2007; Malaria Genomic Epidemiology Net-
work, 2014). Analogous to the randomized trial described above, possession vs. lack of a malaria
protective trait assigns children to an arm in which some malaria illness is prevented vs. not pre-
vented. For possession vs. lack of a trait to be fully analogous to the blood stage vaccine random-
ized trial described above, possession of the trait cannot affect malaria parasitemia incidence just
like assignment to the blood-stage vaccine arm in the randomized trial does not affect malaria para-
sitemia incidence. If the trait affects malaria parasitemia incidence, then it could decrease the Ret-
CM rate not because it decreases coma but because the WHO definition of Ret- CM requires malaria
parasitemia; the natural experiment induced by the trait would then be biased for assessing the
effect of the trait on coma in the same way that a randomized trial is biased if the treatment could
affect the measurement of the outcome (WHO-defined Ret- CM) without affecting the true outcome
of interest (coma without malarial retinopathy). For both BGO and HbAS, it is plausible that the traits
do not protect against malaria parasitemia incidence as systematic reviews have not found consistent
evidence for protection (Uneke, 2007; Taylor et al., 2012); we will assume no protection for our
main analysis but do sensitivity analyses that allow for protection. Under the assumptions that a trait
does not affect malaria parasitemia incidence and the trait is randomly assigned, then if the trait
decreases the probability of developing both Ret+ and Ret- CM, this suggests that malaria parasites
contribute to the pathogenesis of both conditions. If the trait decreases the probability of develop-
ing Ret+ CM but not Ret- CM, this would suggest that malaria parasites are pathogenetic for Ret+
CM but are either not pathogenetic for Ret-CM or the trait affects an aspect of disease not causal to
the development of Ret- CM.
Results
Using data gathered from 1996 to 2007 in a study of CM pathogenesis in Blantyre, Malawi
(Taylor et al., 2004; Seydel et al., 2015) as well as the MalariaGEN consortium (Malaria Genomic
Epidemiology Network, 2008), we compared children with CM to two types of controls – (1) com-
munity controls; (2) hospital controls, children who were admitted to the Paediatric Research Ward
with a known non-malarial cause of illness – meningitis, non-malarial anemia or other non-malaria ill-
ness. Table 1 shows admission characteristics of the hospitalized participants. The Blantyre coma
score is statistically significantly higher in Ret+ CM patients than Ret- CM patients, but we do not
regard the difference as clinically significant. In general, the patients with Ret+ CM were more
severely ill than those with Ret- CM (higher lactate, more deep breathing and a higher chance of
death). The malaria illness is more severe in Ret+ CM than Ret- CM patients (lower platelet count
and more anemia). The higher opening CSF pressures in Ret+ CM patients compared to Ret- CM
patients suggests a higher proportion of Ret+CM patients have increased brain volume. Comparing
CM cases to non-malaria controls, as expected, laboratory abnormalities associated with malaria
infection (e.g. low hematocrit and platelet count) were more frequent in the CM cases.
For each trait t (t=HBAS or blood group O (BGO)), we test the null hypothesis (Ht
0
) that the trait
frequency is the same in controls and true Ret- CM cases vs. the alternative hypothesis (Hta) that the
trait frequency is higher in controls than true Ret- CM cases. Here, true Ret- CM refers to Ret- CM
measured without error; in the actual data, retinopathy status may be measured with error and this
measurement error is taken into account in the inferences (Materials and methods). Under a model
in which the trait does not affect other potential contributors to Ret- CM besides malaria and does
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not affect which CM cases are admitted to the Paedeatric Research Ward (as compared to dying
before reaching the Ward or recovering before being referred to the Ward), the null hypothesis Ht
0
implies that malaria parasitemia is an incidental finding in children with Ret- CM and/or the trait
affects an aspect of disease not causal to development of Ret- CM, while the alternative hypothesis
Hta implies that malaria parasitemia is necessary for some Ret- CM cases and the trait reduces the
pathogenetic potential of malaria infection for Ret- CM. Note that if either HHbAS
0
or HBGO
0
is false,
this implies that malaria parasitemia plays a pathogenetic role in at least some Ret- CM cases.
We calculated HbAS and BGO proportions in study subjects and made inferences about odds
ratios (Table 2) and tested HHbAS
0
and HBGO
0
. For both HbAS and BGO, non-malaria hospitalized con-
trols did not differ from community controls (HbAS p-value=0.86; BGO p-value=0.83); therefore,
subsequent analyses combined the control groups. Controls had a higher proportion of HbAS than
true Ret- CM patients (odds ratio: 14.33, 95% CI: 3.21, 257.24) and true Ret+ CM patients (odds
ratio: 1223.22, 95% CI: 9.87,¥). For BGO, the controls were comparable to true Ret- CM patients
(odds ratio: 1.03, 95% CI: 0.83, 1.29) but higher than true Ret+ CM patients (odds ratio: 1.23, 95%
CI: 1.01, 1.50). There is strong evidence to reject HHbAS
0
(p-value<0.0001) but not HBGO
0
(p-value=0.79);
these results are insensitive to different plausible assumptions about the false discovery rate and
false omission rate for malarial retinopathy (Appendix 1). Taken together, these tests suggest that
Table 2. The top panel displays sickle cell trait (HbAS) proportions in retinopathy-positive (Ret+) cerebral malaria (CM), retinopathy-
negative (Ret-) CM and control groups. The bottom panel displays ABO blood group gene proportions in Ret+ CM, Ret- CM and con-
trol groups. The last two rows of each panel display the odds ratios comparing controls to true Ret+ and true Ret- CM groups, which
account for the fact that there is measurement error in observed retinopathy status (false discovery rate = 0.07 and false omission
rate = 0.05).
Ret+ CM Ret- CM Non-malaria hospital controls Community controls
Sample size 438 287 192 3657
HbAS* 0 1 8 175
HbAA 437 286 184 3482
Proportion of HbAS 0 .003 .042 .048
Odds ratio (95% CI)
Non-malaria hospital controls vs. community controls 0.87 (0.36, 1.78)
Controls vs. true Ret- CM 14.33 (3.21, 257.24)
Controls vs. true Ret+ CM 1223.22 (9.87, ¥)
Ret+ CM Ret- CM Non-malaria hospital controls Community controls
Sample size 433 286 199 3543
Blood Group O 175 135 96 1739
Blood Group A, B or AB 258 151 103 1804
Proportion of Blood Group O .404 .472 .482 .491
Odds ratio (95% CI)
Non-malaria hospital controls vs. community controls 0.97 (0.72, 1.30)
Controls vs. true Ret- CM 1.03 (0.83, 1.29)
Controls vs. true Ret+ CM 1.23 (1.01, 1.50)
* HbAS (sickle cell trait) means that that the person has one normal and one abnormal copy of the hemoglobin beta gene. HbAA means the person has
two normal copies of the hemoglobin beta gene.
DOI: 10.7554/eLife.23699.005
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malaria parasitemia is pathogenic for a proportion of Ret- CM cases. Sickle cell trait protects against
Ret- CM, but blood group O does not.
In Materials and methods, we formulate a sufficient-component cause model (Rothman, 1976)
based on Figure 1 and describe how to make inferences about the fraction of Ret- CM cases that
are due to pathway (b) in Figure 1, i.e., the malaria parasitemia attributable fraction of Ret- CM (the
fraction of Ret- CM cases that would be prevented if malaria parasitemia were eliminated
[Benichou et al., 1998]). The fraction itself cannot be estimated without strong biological assump-
tions (Greenland and Robins, 1988), but a lower bound can be estimated under plausible assump-
tions. Table 3 shows inferences for this lower bound under the main model that assumes the traits
do not protect against malaria parasitemia incidence and sensitivity analyses. Under the main model,
the lower bound is estimated to be .93 with 95% confidence interval (.68, 1). For the sensitivity analy-
ses, although the systematic review of Taylor et al. (2012) found no consistent evidence that HbAS
reduces malaria parasitemia incidence, some studies reviewed found protection and we consider
sensitivity analyses that allow for a small amount of protection (10%) and the largest amount of pro-
tection found in all the studies reviewed (41%) (Ntoumi et al., 1997). Also, the sensitivity analyses
vary the false discovery rate and false omission rate between 0 and the upper bound estimated in
Materials and methods. Under all scenarios considered, we found evidence for a substantial contri-
bution of malaria parasites to the pathogenesis of Ret- CM with lower 95% confidence bounds rang-
ing from .37 to .77 and point estimates for the lower bound ranging from .86 to .95.
Discussion
We have studied a natural experiment that alters the level of malaria illness and found evidence that
children with genetic traits associated with resistance to malaria illness are underrepresented in
admissions with both Ret+ and Ret- CM (HbAS) or in admissions with Ret+ CM only (BGO).
Table 3. Inferences for lower bound on malaria parasitemia attributable fraction of Ret- CM (fraction of Ret- CM cases that would be
prevented if malaria parasitemia were to be eliminated) under the sufficient-component cause model based on Figure 1 presented in
Materials and methods. Inferences under the main model and sensitivity analyses that vary the effect of HbAS on malaria parasitemia
incidence rate, the false discovery rate (FDR) and the false omission rate (FOR) for malarial retionopathy.
Effect of HbAS on malaria
parasitemia incidence rate FDR FOR
Lower bound on malaria parasitemia
attributable fraction of Ret-
CM Estimate (95% CI)
Main Model
No Effect .07 .05 .93 (.68, 1)
Sensitivity Analyses
Reduce 10% .07 .05 .92 (.64, 1)
Reduce 41% .07 .05 .88 (.46, 1)
No Effect .30 .11 .94 (.75, 1)
Reduce 10% .30 .11 .94 (.72, 1)
Reduce 41% .30 .11 .91 (.58, 1)
No Effect 0 .11 .92 (.62, 1)
Reduce 10% 0 .11 .91 (.58, 1)
Reduce 41% 0 .11 .86 (.37, 1)
No Effect .30 0 .95 (.77, 1)
Reduce 10% .30 0 .94 (.74, 1)
Reduce 41% .30 0 .91 (.61, 1)
No Effect 0 0 .92 (.66, 1)
Reduce 10% 0 0 .92 (.63, 1)
Reduce 41% 0 0 .87 (.44, 1)
DOI: 10.7554/eLife.23699.006
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Figure 1 shows a model of how HbAS and BGO affect Ret- and Ret+ CM. HbAS protects children
with malaria parasitemia from developing uncomplicated malaria illness (e.g., fever) and severe
malaria illness (Taylor et al., 2012). By contrast, current evidence suggests that BGO has no effect
on developing uncomplicated malaria illness (Uneke, 2007), but does inhibit the cytoadherence of
parasitized red blood cells to endothelial cells in the microcirculation, e.g., by affecting rosetting
(Rowe et al., 2007) and physical properties of the red cell membrane (Me´ndez et al., 2012),
thereby preventing severe malaria illness (Cserti and Dzik, 2007; Migot-Nabias et al., 2000;
Uneke, 2007). Consistent with this current evidence, in Figure 1, HbAS prevents Ret- CM through
pathway (b), which involves two components (uncomplicated malaria illness + other illness), by pre-
venting one of the components, uncomplicated malaria illness, whereas BGO does not protect
against Ret- CM through pathway (b) because it does not prevent uncomplicated malaria illness
(Figure 1).
In Figure 1 pathway (b), Ret- CM results from an interaction between malaria illness and other ill-
ness. While the interactions between malaria parasites and other pathogens are incompletely under-
stood and not well investigated, there is evidence for interaction (Obaro and Greenwood, 2011;
Mallewa et al., 2013; Postels and Birbeck, 2011). In studies of sepsis and malaria, the effect of
microvascular parasite sequestration on the integrity of the gut mucosa is thought to allow bacterial
seeding into the blood stream and hence bacteremia (Scott et al., 2011). Another example is that
following antigenic challenge from a Plasmodium falciparum candidate vaccine, children coinfected
with schistosomiasis had lower acquired specific immune responses than those not infected
(Diallo et al., 2010).
Another way in which malaria parasitemia could play a causal role in Ret- CM besides pathway (b)
in Figure 1 is that the parasitemia could be the sole cause of coma. Taylor et al. (2004)’s autopsy
study results suggest that among children dying from Ret- CM, malaria parasitemia is typically not
the sole cause of death (see Causes of Death in Autopsy study in Appendix 1), but it is possible that
in survivors from Ret- CM, malaria parasitemia is the major contributor to acute illness. Whether
malarial retinopathy is present or absent in CM could be affected by factors such as the child’s
genome, the parasite’s genome and the child’s previous exposures to malaria (Postels and Birbeck,
2011). The protection provided against Ret- CM by HbAS but not BGO could be explained by an
interaction between the factor(s) affecting whether malarial retinopathy is present and BGO, e.g., a
parasite genotype which causes malarial retinopathy to be absent could interfere with the mecha-
nism by which BGO provides protection against severe malaria.
Our study has several limitations. We only considered the genetic variants of sickle cell trait and
blood group because these were the only statistically significant (p<.05) protective variants in the
Malawi sample on which malarial retinopathy was measured, but future work could further test the
model in Figure 1 by looking at additional genetic variants that have been found to affect the risk of
malaria in other sites in Africa (Malaria Genomic Epidemiology Network, 2014). Our study only
addresses CM pathogenesis in children. Adult and pediatric CM have important clinical differences
and our results may not be generalizable to adults with Ret- CM. Detection of the presence or
absence of malarial retinopathy was determined by several ophthalmologists over the 11 year dura-
tion of data collection, the sensitivity of detection of retinal changes may have varied between prac-
titioners. Malarial retinopathy was determined on the basis of ophthalmoscopy alone, but since the
time of our study, techniques such as optical coherence tomography that may increase sensitivity
have been developed (Joshi et al., 2017). We measure malarial retinopathy at the time of admis-
sion, but patients are admitted at different points on the disease trajectory. Malarial retinopathy can
change over time; it doesn’t resolve during the 2–4 days of hospitalization but can become worse,
which is a poor prognostic sign. Although there are limitations in our study to the sensitivity with
which malarial retinopathy is measured, even if a moderate number of Ret- CM cases should be Ret
+ CM cases in Table 2, e.g., if the false omission rate is .5 and the false discovery rate is 0, there is
still strong evidence that HbAS has a protective effect for Ret- CM (p-value=0.007; odds ratio: 6.81,
95% CI: (1.50, ¥)). Our main analysis assumed that possession of HbAS or BGO does not affect
malaria parasitemia incidence; however, sensitivity analyses showed that our results were not sensi-
tive to plausible violations of this assumption. Our analysis assumed that HbAS and BGO do not
have selection effects on which CM cases are admitted to the Paediatric Research Ward as opposed
to dying before reaching the Paedieatric Research Ward or being cured before needing to be
referred to the ward; another interpretation of our study is that instead of studying ‘cerebral malaria’
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as such, we have studied, ‘cerebral malaria mild enough to make it to the ward but severe enough
not to recover without being taken to the ward.’ Some of the non-malaria hospital controls had
malaria parasitemia; since children can sometimes develop severe malaria with relatively low levels
of parasitemia, it is possible that malaria contributed to the illness in these control participants. Fur-
thermore, older non-malaria hospital controls may have a selection bias for HbAS since they have
survived to an older age (Ackerman et al., 2005). Our results are robust to considering only the
community controls (Appendix 1—table 4) which do not suffer from these potential biases of the
non-malaria hospital controls.
In summary, we studied a natural experiment that alters the level of malaria illness experienced
by children through genetic variation and found evidence that malaria parasitemia is on the causal
pathway to a substantial proportion of Ret- CM cases. Our approach of using genetically inherited
traits to study CM pathogenesis could be adapted to illuminate the pathogenesis of other diseases.
Materials and methods
Setting and study participants
The study sample includes children with WHO-defined CM from 1997 to 2007 who were admitted to
the Paediatric Research Ward at Queen Elizabeth Central Hospital, a tertiary referral center and
teaching hospital in Blantyre, Malawi. The WHO definition of CM requires coma, circulating Plasmo-
dium falciparum parasites, and no other cause of coma evident either by history or physical examina-
tion. Patients were enrolled during the rainy season, the time of annual peak incidence of CM. All
patients were treated with intravenous quinine as standard antimalarial therapy. Enrollment in the
study required explicit written consent from the parent or guardian. There were 947 enrolled
patients. Malarial retinopathy was assessed on 726 of these patients and we subsequently limited
our analysis to these 726 patients. To assess retinal changes, direct and indirect ophthalmoscopy
were performed by an ophthalmologist well versed in findings typical of malarial retinopathy.
We consider two types of controls in the study. The first type are community controls – 3704 chil-
dren intended to be representative of the populations to which the cases belonged. Community
controls were cord blood samples from Queen Elizabeth Central Hospital, mostly from the newborn
nursery. The second type of controls are 194 patients who were admitted during the study period to
the Paediatric Research Ward at Queen Elizabeth Central Hospital with a non-malarial cause of ill-
ness – meningitis, non-malarial anemia or other non-malaria illness.
Advantages of considering two control groups
Two sources of bias in case-control studies are hidden bias (unmeasured confounding) and selection
bias (Rosenbaum, 1987, Rosenbaum, 2002). Hidden bias occurs when there are unmeasured vari-
able(s) that are associated with the exposure and the outcome. Selection bias occurs when control
subjects are selected based on a variable that is affected by the exposure. Different control groups
might be subject to different amounts of hidden bias and selection bias. If two such control groups
have similar exposure rates, this provides evidence against hidden bias and selection bias (Rose-
nbaum, 1987). Further, if the case group has a different exposure rate than both control groups and
the control groups have similar exposure rates, this provides stronger evidence that the exposure
has a causal effect on the outcome, rather than the results being biased by hidden bias or selection
bias, as compared to a study with a single control group (Rosenbaum, 1987).
Community controls are less likely to suffer from selection bias than the hospital controls. Com-
munity controls were randomly selected from the same population as the cases. In contrast, hospital
controls could suffer from selection bias if the genetic variant of interest was associated with a non-
malaria illness – this type of selection bias is known as Berkson’s bias (Westreich, 2012; Berk-
son, 1946). Although the hospital controls might suffer from more selection bias than the commu-
nity controls, the hospital controls have the potential advantage that they would reduce hidden bias
if there was population stratification such that the genetic variant was associated with an unmea-
sured population stratification feature (e.g., housing conditions) that caused both malaria and non-
malaria illness.
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Genotypes
Participants were genotyped using the Sequenom iPLEX MassARRAY platform (Malaria Genomic
Epidemiology Network, 2014). The genotyping included 55 SNPs for which there were previously
reported associations with severe malaria. Two of the SNPs were found to be
statistically significantly (p<.05) associated with cerebral malaria in Malawi – HBB rs334, which enco-
des the sickle cell trait, and ABO rs8176719, which encodes the blood type (O vs. A, B or AB); see
Figure 1 in Malaria Genomic Epidemiology Network (2014). These two SNPs were used in our
analysis.
Hypotheses
For a given genetically inherited trait, we consider two competing hypotheses for testing whether
malaria parasitemia plays a pathogenic role in Ret- CM. We assume a biological model under which
the trait does not affect other illnesses that cause Ret- CM and under which the trait does not have a
selection effect on which CM cases are admitted to the Paedieatric Research Ward vs. dying before
reaching the Paediatric Research Ward or being cured before needing to be referred to the ward.
Null hypothesis
Malaria parasitemia is an incidental finding in children with true Ret- CM and/or the genetic trait
affects an aspect of disease not causal to development of true Ret- CM.
Let lt:rþ be the probability that a child with true Ret+ CM has a trait t (e.g., t could be the sickle
cell trait or blood type O), lt:r  the probability that a child with true Ret- CM has the trait t and lt:co
the probability that a control child has the trait t. For the observed data, we take into account that
malarial retinopathy may be measured with error. Among children with WHO-defined CM, let FDR
be the false discovery rate that a child who is found by the examining ophthalmologist to have Ret+
CM actually has Ret- CM and let FOR be the false omission rate that a child who is found by the
examining ophthalmologist to have Ret- CM actually has Ret+ CM.
Suppose malaria parasitemia is an incidental finding in patients with true Ret- CM and/or the trait
affects an aspect of malaria infection not experienced by Ret- CM patients. Then the probability of
the trait would be the same in controls as in patients with true Ret- CM, lt:r  ¼ lt:co. If this is the
case, we have the following probabilities for observing the trait in the observable groups:
PðControl has traitÞ ¼lt:co
PðRetþCM patient has traitÞ ¼ð1 FDRÞ lt:rþþFDR lt:co
PðRet CM patient has traitÞ ¼FOR lt:rþþð1 FORÞ lt:co
Alternative hypothesis
Malaria parasitemia is pathogenic for true Ret- CM and the trait reduces the pathogenic potential of
malaria infection for true Ret- CM.
If malaria parasitemia is pathogenic for true Ret- CM and the trait reduces the pathogenic poten-
tial of malaria infection for true Ret- CM, then the trait will reduce the probability of true Ret- CM,
lt:r <lt:co. We have the following probabilities for observing the trait in the observable groups:
PðControl has traitÞ ¼lt:co
PðRetþCM patient has traitÞ ¼ð1 FDRÞ lt:rþþFDR lt:r 
PðRet CM patient has traitÞ ¼FOR lt:rþþð1 FORÞ lt:r 
To estimate FDR and FOR, we use data from Beare et al., 2002 who compared two ophthalmolo-
gists’ concordance in grading malarial retinopathy. As described in the next section, we obtain point
estimates of .07 and .05 and upper bound estimates of .30 and .11 for FDR and FOR respectively;
the main analyses use the point estimates and additional analyses use the upper bound estimates.
For fixed values of FDR and FOR, we estimate the parameters lt:rþ, lt:r  and lt:co by maximum
likelihood.
Estimating false discovery and false omission rates for malarial
retinopathy
We use data on 65 patients at Queen Elizabeth Central Hospital in Blantyre, Malawi who were each
examined by two ophthalmologists (Beare et al., 2002). Malarial retinopathy is diagnosed if any of
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the following six signs are present: retinal hemorrhages (RH), macular whitening (MW), foeval whiten-
ing (FW), peripheral whitening (PW), vessel changes (VC) and capillary whitening (CW). RH, VC and
CW require little observer judgement if they are seen, but they may not be seen, depending on the
degree of pupillary dilation and the presence/absence of spontaneous eye movements; for these
consider the specificity to be 1 (Beare et al., 2002). Identifying MW, FW and PW requires more
experience on the part of the observer; MW and FW are more reproducible, and PW is less so
(Beare et al., 2002).
We first consider the false discovery rate. To estimate an upper bound on the false discovery
rate, we assumed that if RH, VC or CW was detected by either ophthalmologist, there was true
malarial retinopathy, but if MW, FW or PW was detected without RH, VC or CW, then it was a false
discovery; this is likely an overestimate since in some cases where MW, FW or PW was detected
without RH, VC or CW, there is likely true malarial retinopathy that was missed by RH, VC and CW.
There were 39 patients diagnosed by ophthalmologist 1 with malarial retinopathy, 33 of whom had
RH, VC or CW by at least one ophthalmologist and there were 36 patients diagnosed by ophthal-
mologist 2 with malarial retinopathy, 33 of whom had RH, VC or CW by at least one ophthalmolo-
gist. To find a conservative upper bound on the false discovery rate, we consider ophthalmologist 1
and found the 95% Wilson binomial confidence interval (Wilson, 1927) based on 6 out of 39 false
discoveries, resulting in an 95% confidence interval of (0.07, 0.30), so resulting in an upper bound of
0.30 for the false discovery rate. To find a point estimate for the false discovery rate, we assume that
there was true malarial retinopathy if RH, VC or CW was detected by either ophthalmologist or if
FW was detected by both ophthalmologists or if MW was detected by both ophthalmologists since
FW and MW were found to be reproducible by Beare et al., 2002, and then we averaged the result-
ing point estimates for the false discovery rate for the two ophthalmologists ((4/39 + 1/36)/2), to
obtain an estimate of .07.
We next consider the false omission rate. To estimate an upper bound on the false omission rate,
we estimate an upper bound on the false omission rate if we were to only use RH, VC and CW to
diagnose malarial retinopathy. The actual false omission rate is likely to be at least as small because
we also diagnose malarial retinopathy if there’s any of MW, FW or PW and we think that the majority
of time when we find MW, FW or PW but not RH, VC and CW, there is true malarial retinopathy,
whereas a false omission will be relatively rare. We assume that the false positive rate for RH, VC
and CW is 0 and use a model similar to model 1 in Nedelman (1988). Specifically, let  denote the
prevalence of true malarial retinopathy and z the false negative probability that an ophthalmologist
will fail to detect RH, VC or CW in a child with true malarial retinopathy. Assume that we have two
independent ophthalmologists. Then, the probability that both ophthalmologists will detect at least
one of RH, VC or CW is  1  zð Þ2, the probability that one but not the other ophthalmologist will
detect RH, VC or CW is 2 z 1  zð Þand the probability that both ophthalmologists will detect none of
RH, VC or CW is  z2 þ 1   . The false omission rate is FOR ¼  z
1  þ z. We found a point estimate of
0.05 for the false omission rate and a 95% confidence interval (using the percentile bootstrap) of
(0, .11). Thus we take .11 as an estimated upper bound for the false omission rate and .05 as a point
estimate for the false omission rate, recognizing that it is likely to be an upwardly biased point
estimate.
Statistical inference
We will test the null hypothesis Ht
0
:lt:r  ¼ lt:co(the probability of the malaria resistance trait t is the
same in true Ret- CM cases as controls) versus the alternative hypothesis Hta:lt:r <lt:co (the probabil-
ity of the malaria resistance trait t is lower in true Ret- CM cases than controls). To test these hypoth-
eses, we will estimate the parameters under the null and alternative hypotheses by maximum
likelihood and use the generalized likelihood ratio test with 1 degree of freedom (Rice, 2007). The
maximum likelihood estimation takes into account the assumed false discovery rate and false omis-
sion rate for malarial retinopathy detection. We will form confidence intervals for the odds ratios of
the trait among controls vs. true Ret- CM patients ( lt:co= 1  lt:coð Þf g= lt:r = 1  lt:r ð Þf g½ and the odds
ratio of the trait among controls vs. true Ret+ CM patients lt:co= 1  lt:coð Þf g= lt:rþ= 1  lt:rþð Þf g½  by
inverting the generalized likelihood ratio test. We will use Fisher’s exact to test whether the odds
ratio of the trait differs among the community controls vs. the non-malaria illness controls and con-
struct a 95% confidence interval for this odds ratio.
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Inference for malaria parasitemia attributable fraction for coma among
Ret- CM Cases
The malaria parasitemia attributable fraction for coma among Ret- CM cases is the fraction of coma
that would be prevented if malaria parasitemia were to be eliminated among Ret- CM cases. We for-
mulate a model using the sufficient-component cause framework (Rothman, 1976) and estimate the
malaria parasitemia attributable fraction for Ret- CM using this model. A sufficient cause for a dis-
ease is a set of conditions that inevitably produces the disease. We assume that Ret+ CM can be
represented by one sufficient cause: malaria parasitemia + factors that lead the malaria parasitemia
to develop into uncomplicated malaria illness (e.g., lack of immunity) + factors that lead the uncom-
plicated malaria illness to further progress to complicated malaria illness with coma and malarial reti-
nopathy (e.g., genetic complexity of the malaria infection that overwhelms a child’s ability to control
the infection). We assume that Ret- CM can be represented by two sufficient causes: (a) malaria par-
asitemia + another illness that is sufficient, in and of itself, to produce coma without malarial retinop-
athy; (b) malaria parasitemia + factors that lead the malaria parasitemia to develop into
uncomplicated malaria illness + second insult (innate or acquired) that combined with the uncompli-
cated malarial illness leads to a coma without malarial retinopathy but which would not in and of
itself be sufficient to produce coma. These two sufficient causes (a) and (b) for Ret- CM correspond
to pathways (a) and (b) to Ret- CM in Figure 1. Let p be the proportion of Ret- CM from sufficient
cause (b), which is the malaria parasitemia attributable fraction for coma among Ret- CM cases.
Let rt;p be the factor by which the trait t multiplies the risk of malaria parasitemia (i.e., relative risk
of malaria parasitemia for individuals with trait t compared to individuals without trait t),rt;u be the
factor by which the trait multiplies the risk of factors that lead the malaria parasitemia to develop
into uncomplicated malaria illness conditional on having malaria parasitemia, rt;c be the factor by
which the trait multiplies the risk of factors that lead uncomplicated malaria illness to further prog-
ress to complicated malaria illness with coma and malarial retinopathy, rt;a be the factor by which the
trait multiplies the risk of another illness that is sufficient, in and of itself, to produce coma without
malarial retinopathy in the presence of malaria parasitemia and rt;s be the factor by which the trait
multiplies the risk of a second insult that combined with uncomplicated malaria illness leads to a
coma without malaria retinopathy but which would not in and of itself be sufficient to produce
coma. We assume that rt;u; rt;c  1, i.e., that the trait has no effect or a beneficial effect in preventing
uncomplicated and complicated malaria.
Let lt be the proportion of trait t in the population. For a rare disease, this proportion is approxi-
mately the proportion of trait t among the controls, lt » lt:co. Ret+ CM and Ret- CM are both rare
diseases – the vast majority of malaria infections do not progress to cerebral malaria; subsequently
we assume lt ¼ lt:co. We then have
lt:rþ ¼
rt;prt;urt;clt:co
rt;prt;urt;clt:coþ 1 lt:co
lt:r  ¼ 1  pð Þ
rt;prt;alt:co
rt;prt;alt:coþ 1 lt:co
þ p
rt;prt;urt;slt:co
rt;prt;urt;slt:coþ 1 lt:co
For our main model, we make the following assumptions: (i) rt;p ¼ 1 – the trait has no effect on
malaria parasitemia; (ii) rt;a ¼ 1 – the trait has no effect on illnesses that are sufficient in and of them-
selves to produce coma without malarial retinopathy in the presence of malaria parasitemia and (iii)
rt;s ¼ 1 – the trait has no effect on an insult that combined with uncomplicated malaria illness leads to
a coma without malaria retinopathy but which would not in and of itself be sufficient to produce
coma. We relax the assumption that rt;p ¼ 1 in sensitivity analyses. Under assumptions (i)-(iii),
lt:rþ ¼
rt;urt;clt:co
rt;urt;clt:coþ1 lt:co
lt:r  ¼ 1  pð Þlt:coþ p
rt;ult:co
rt;ult:coþ1 lt:co
(1.1)
The parameters lt:co;lt:rþ ;lt:r  can be identified from the data and thus Equation (1.1) involve
two equations in three unknowns (p; rt;u; rt;c). The p is minimized (and hence the malaria parasitemia
attributable fraction for coma among Ret- CM cases, is minimized) by letting rt;c ¼ 1, specifically the
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minimizing p solves lt:r  ¼ 1  pð Þlt:coþ plt:rþ . Let plb;t represent this lower bound on p based on trait
t, which is a function of lt:co;lt:rþ ;lt:r ð Þ; let plb;t0 represent this lower bound on p based on another
trait t0, which is a function of lt0:co;lt0:rþ ;lt0:r ð Þ and let plb ¼min plb;t;plb;t0
  
be the lower bound on p
based on both traits, which is a function of lt:co;lt:rþ ;lt:r ð ,lt0:co;lt0:rþ ;lt0:r Þ. We estimate plb by maxi-
mum likelihood and form a 95% confidence interval by inverting the generalized likelihood ratio test
for plb.
We conduct sensitivity analyses that allow for rt;p<1. Maintaining the assumptions (ii) rt;a ¼ 1 and
(iii) rt;s ¼ 1, we have that the lower bound on p solves
lt:r  ¼ 1  pð Þ
rt;plt:co
rt;plt:coþ 1 lt:co
þ plt:rþ
Software
The supplemental file rcode_for_paper.R contains R (R Development Core Team, 2016) code for
replicating the analyses in our paper.
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Appendix 1
Supplemental results
Sample sizes and missing data proportions
Appendix 1—table 1 shows the sample sizes of the Ret+ CM, Ret- CM, non-malaria hospital
controls and community controls. Appendix 1—table 2 shows the proportion of missing
data on the genetic traits for each of these four groups. Appendix 1—table 3 shows the
proportion of missing data on the demographic and clinical variables for the Ret+ CM, Ret-
CM and non-malaria hospital control groups.
Appendix 1—table 1. Sample sizes.
Retinopathy-
positive CM
Retinopathy-
negative CM
Non-malaria hospital
controls
Community
controls
Sample
Size
438 288 204 3704
DOI: 10.7554/eLife.23699.008
Appendix 1—table 2. Missing data proportions for genetic traits.
Retinopathy-
positive CM
Retinopathy-
negative CM
Non-malaria hospital
controls
Community
controls
Sickle Cell
Trait
.002 0 .054 .010
Blood
Group
.011 .003 .025 .043
DOI: 10.7554/eLife.23699.009
Appendix 1—table 3. Missing data proportions for demographic and clinical variables.
Retinopathy-
positive CM
Retinopathy-
negative CM
Non-malaria hospital
controls
Female .018 .021 .005
Age (months) 0 0 .005
Mid-upper arm circumference
(cm)
.016 .014 .054
Weight (kg) 0 0 0
Height (cm) .009 .024 .034
Temperature (˚C) 0 0 0
Pulse rate – beats/minute .002 0 .010
Respiratory rate – breaths/
minute
0 0 .005
Liver size – cm below costal
margin
.009 .024 .010
Spleen size – cm below costal
margin
.005 .014 .010
Deep breathing .007 .021 0
Blantyre Coma Score: 0 0 0
CSF opening pressure – mm of
water
.420 .330 .623
Hematocrit – % .009 .024 .034
Platelets .153 .160 .132
Malaria parasitemia – para-
sites/mm3
.039 .042 .025
Appendix 1—table 3 continued on next page
Small et al. eLife 2017;6:e23699. DOI: 10.7554/eLife.23699 17 of 18
Short report Epidemiology and Global Health
Appendix 1—table 3 continued
Retinopathy-
positive CM
Retinopathy-
negative CM
Non-malaria hospital
controls
White blood cells .082 .097 .118
Lactate – mmol/liter .653 .753 .564
Blood glucose – mmol/liter .014 .003 0
CSF white cell count – %  5 .277 .170 .275
Blood culture positive for
pathogen
.039 .024 .059
HIV positive .144 .153 .353
Discharge outcome 0 .007 0
DOI: 10.7554/eLife.23699.010
Causes of death in autopsy study
For children dying with Ret+ CM, among the children with cerebral sequestration, one had
pneumonia and one had pneumonia and meningoencephalitis. The one child with Ret+CM
but without cerebral sequestration had a likely cause of death of anemia. Six children with
Ret+CM and cerebral sequestration had severe anemia which was thought to be due to
malaria parasitemia. Among the 15 children dying with Ret- CM, three had Reye’s syndrome
and pneumonia, three had pneumonia alone, one had pneumonia with spread to meninges,
one had pneumonia with meningoencephalitis, one had hepatic necrosis, one had hepatitis,
one had skull fractures, one had subdural/intracerebral hematomas, one had left ventricular
failure with pulmonary edema, one had septicemia and one had an unknown cause of death.
Sensitivity to assumptions about false discovery rate and false
omission rates for detecting malarial retinopathy
For testing the null hypothesis vs. the alternative hypothesis for the sickle cell trait, the p-value
remains below. 0001 as FDR and FOR are varied up to the upper bounds of .30 and .11
respectively. For blood group O, the p-value increases to 0.94 when FDR and FOR are set
at their upper bounds of .30 and .11 respectively.
Results using community controls only
Appendix 1—table 4 shows the inferences from our model for comparing true Ret+ CM to
controls and true Ret- CM to controls (Materials and methods) when we use only the
community controls.
Appendix 1—table 4. Odds ratio comparing community controls to true Ret+ CM and Ret-
CM groups, which account for the fact that there is measurement error in observed retinopathy
status (false discovery rate = 0.07 and false omission rate = 0.05). The p-values are two-sided
p-values for testing that the odds ratio equals 1.
Odds ratio (95% CI) p-value
HbAS
Controls vs. true Ret- CM 14.43 (3.23, 258.94) <0.0001
Controls vs. true Ret+ CM 1234.96 (9.93,¥) <0.0001
BGO
Controls vs. true Ret- CM 1.03 (0.83, 1.29) 0.79
Controls vs. true Ret+ CM 1.23 (1.01, 1.51) 0.04
DOI: 10.7554/eLife.23699.011
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